Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from China Life Insurance Co ( (HK:2628) ).
China Life Insurance Company Limited plans to form a RMB8.5 billion investment partnership with affiliated entity China Life Qiyuan, in which China Life will act as the limited partner contributing RMB8.4915 billion, while China Life Qiyuan will serve as general and managing partner with a RMB8.5 million stake, and China Life Everbright Investment Management (CLEI) appointed as manager. Classified as a connected transaction under Hong Kong listing rules due to common control by China Life Insurance (Group) Company, the deal is subject only to reporting and announcement requirements—without independent shareholder approval—reflecting the insurer’s internal asset allocation strategy and long-term capital deployment over a 15-year partnership term, with a defined investment, operation and exit schedule funded from internal resources.
The most recent analyst rating on (HK:2628) stock is a Buy with a HK$39.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.
More about China Life Insurance Co
China Life Insurance Company Limited is a leading life insurance provider in mainland China, offering a broad range of life and health insurance products and related financial services. Listed in Hong Kong, the company operates as part of the China Life group, with its controlling shareholder China Life Insurance (Group) Company holding a majority stake, and focuses on long-term insurance and investment-related businesses within the Chinese market.
Average Trading Volume: 63,541,324
Technical Sentiment Signal: Buy
Current Market Cap: HK$1375.2B
Find detailed analytics on 2628 stock on TipRanks’ Stock Analysis page.